Information Provided By: 
Fly News Breaks for February 9, 2016
SNY, REGN
Feb 9, 2016 | 12:25 EDT
Piper Jaffray analyst Edward Tenthoff noted that Regeneron (REGN) is guiding for 20% EYLEA growth in 2016 and that the launch of its Praluent cholesterol drug with partner Sanofi (SNY) has been even slower than expected. Tenthoff keeps a Neutral rating on Regeneron shares and lowered his price target on the stock to $443 from $607 following the company's earnings report and guidance.
News For REGN;SNY From the Last 2 Days
SNY
Apr 22, 2024 | 12:15 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
SNY
Apr 22, 2024 | 11:36 EDT
